Press Releases

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Mestag Therapeutics and VIB enter into an exclusive partnership in oncology

Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair

Mestag Therapeutics founding investigator Prof. David A. Tuveson elected to US National Academy of Medicine

Fierce Biotech names Mestag Therapeutics as one of its “Fierce 15” Biotech Companies of 2021

Mestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures

Mestag Therapeutics announces collaboration with Janssen, focused on the discovery of novel fibroblast targets for the treatment of inflammatory disease

Mestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer

Mestag Therapeutics congratulates Founder Professor David A. Tuveson upon his appointment as 2021 President of The American Association for Cancer Research